DK3661514T3 - Mavacamten til behandling af hypertrofisk kardiomyopati - Google Patents

Mavacamten til behandling af hypertrofisk kardiomyopati

Info

Publication number
DK3661514T3
DK3661514T3 DK18759209.2T DK18759209T DK3661514T3 DK 3661514 T3 DK3661514 T3 DK 3661514T3 DK 18759209 T DK18759209 T DK 18759209T DK 3661514 T3 DK3661514 T3 DK 3661514T3
Authority
DK
Denmark
Prior art keywords
mavacamten
treatment
hypertrophic cardiomyopathy
hypertrophic
cardiomyopathy
Prior art date
Application number
DK18759209.2T
Other languages
Danish (da)
English (en)
Inventor
Marc J Semigran
June H Lee
Joseph Lambing
Eric Green
Marc Evanchik
Timothy Carlson
David Zhang
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Application granted granted Critical
Publication of DK3661514T3 publication Critical patent/DK3661514T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
DK18759209.2T 2017-08-04 2018-08-03 Mavacamten til behandling af hypertrofisk kardiomyopati DK3661514T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762541591P 2017-08-04 2017-08-04
US201762584537P 2017-11-10 2017-11-10
US201862639922P 2018-03-07 2018-03-07
US201862671585P 2018-05-15 2018-05-15
PCT/US2018/045180 WO2019028360A1 (en) 2017-08-04 2018-08-03 MAVACAMTEN FOR USE IN THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY

Publications (1)

Publication Number Publication Date
DK3661514T3 true DK3661514T3 (da) 2025-12-15

Family

ID=63350605

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18759209.2T DK3661514T3 (da) 2017-08-04 2018-08-03 Mavacamten til behandling af hypertrofisk kardiomyopati

Country Status (28)

Country Link
US (6) US20200054636A1 (https=)
EP (2) EP3661514B1 (https=)
JP (3) JP2020529996A (https=)
KR (2) KR20200035973A (https=)
CN (2) CN111182901A (https=)
AU (2) AU2018311974B2 (https=)
CA (1) CA3071948A1 (https=)
DK (1) DK3661514T3 (https=)
ES (1) ES3055679T3 (https=)
FI (1) FI3661514T3 (https=)
HR (1) HRP20251598T1 (https=)
HU (1) HUE073047T2 (https=)
IL (2) IL322175A (https=)
LT (1) LT3661514T (https=)
MA (1) MA49760B1 (https=)
MX (3) MX2020001406A (https=)
MY (1) MY208231A (https=)
PL (1) PL3661514T3 (https=)
PT (1) PT3661514T (https=)
RS (1) RS67534B1 (https=)
RU (1) RU2020109345A (https=)
SG (2) SG10202112960QA (https=)
SI (1) SI3661514T1 (https=)
SM (1) SMT202500413T1 (https=)
TW (1) TWI907332B (https=)
UA (1) UA130213C2 (https=)
UY (1) UY37834A (https=)
WO (1) WO2019028360A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
WO2020257609A1 (en) * 2019-06-21 2020-12-24 MyoKardia, Inc. Diagnostics and treatments for cardiac disease
CN110698415B (zh) * 2019-10-21 2023-05-09 上海先行医药开发有限公司 一种肌球蛋白抑制剂及其制备方法和用途
EP4054588A4 (en) * 2019-11-10 2023-12-13 MyoKardia, Inc. Methods of treatment with myosin modulator
HUE069154T2 (hu) * 2020-01-28 2025-02-28 Assia Chem Ind Ltd A mavakamten szilárd állapotú formái és eljárás elõállításukra
MX2023002024A (es) * 2020-08-28 2023-05-10 Myokardia Inc Métodos de tratamiento con modulador de miosina.
WO2022105852A1 (zh) 2020-11-20 2022-05-27 江苏恒瑞医药股份有限公司 三嗪二酮类衍生物、其制备方法及其在医药上的应用
US20240082248A1 (en) * 2021-02-01 2024-03-14 Dr. Reddy's Laboratories Limited Process for preparation of mavacamten and solid state forms thereof
CN117083275A (zh) 2021-03-04 2023-11-17 赛特凯恩蒂克公司 心脏肌节抑制剂
CN112939876A (zh) * 2021-03-10 2021-06-11 杭州科巢生物科技有限公司 Mavacamten的晶型I及其制备方法
WO2022189599A1 (en) 2021-03-12 2022-09-15 Sandoz Ag Crystalline forms of mavacamten for the treatment of hcm
PT4370116T (pt) * 2021-07-16 2025-03-14 Cytokinetics Inc Regimes de administração de aficamten para o tratamento da cardiomiopatia hipertrófica obstrutiva
US20240389972A1 (en) * 2021-09-24 2024-11-28 Koninklijke Philips N.V. METHODS AND SYSTEMS FOR GENERATING LIKELIHOOD OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF)
JP2025534288A (ja) 2022-09-26 2025-10-15 エッジワイズ セラピューティクス, インコーポレイテッド 1,4-ジヒドロキナゾリノン化合物およびその使用
WO2024097284A1 (en) * 2022-11-02 2024-05-10 MyoKardia, Inc. Mavacamten and derivatives thereof for use in treating atrial dysfunction
EP4688756A1 (en) 2023-03-27 2026-02-11 Edgewise Therapeutics, Inc. Quinazoline dione compounds and uses thereof
WO2024206339A1 (en) 2023-03-27 2024-10-03 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202000071T1 (it) * 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache

Also Published As

Publication number Publication date
IL272300B1 (en) 2025-08-01
EP4659806A2 (en) 2025-12-10
MX2024000348A (es) 2024-01-26
CN118593507A (zh) 2024-09-06
LT3661514T (lt) 2025-11-10
US20260007671A1 (en) 2026-01-08
MA49760B1 (fr) 2025-11-28
PL3661514T3 (pl) 2026-02-23
AU2024203872A1 (en) 2024-06-27
US20200054636A1 (en) 2020-02-20
IL272300A (en) 2020-03-31
CA3071948A1 (en) 2019-02-07
RS67534B1 (sr) 2026-01-30
MY208231A (en) 2025-04-25
EP3661514A1 (en) 2020-06-10
HRP20251598T1 (hr) 2026-01-30
SI3661514T1 (sl) 2026-01-30
JP2025020292A (ja) 2025-02-12
SG11202000549TA (en) 2020-02-27
MA49760A (fr) 2020-06-10
US20240423981A1 (en) 2024-12-26
AU2018311974A1 (en) 2020-02-06
SMT202500413T1 (it) 2025-11-10
CN111182901A (zh) 2020-05-19
EP4659806A3 (en) 2026-02-18
FI3661514T3 (fi) 2025-12-12
IL272300B2 (en) 2025-12-01
JP2023065372A (ja) 2023-05-12
KR20250116181A (ko) 2025-07-31
RU2020109345A (ru) 2021-09-06
PT3661514T (pt) 2025-12-10
JP2020529996A (ja) 2020-10-15
US20220226324A1 (en) 2022-07-21
KR20200035973A (ko) 2020-04-06
WO2019028360A1 (en) 2019-02-07
MX2020001406A (es) 2020-03-09
AU2018311974B2 (en) 2024-03-07
SG10202112960QA (en) 2021-12-30
HUE073047T2 (hu) 2025-12-28
TWI907332B (zh) 2025-12-11
MX2024008096A (es) 2024-07-15
EP3661514B1 (en) 2025-09-17
TW201916882A (zh) 2019-05-01
UA130213C2 (uk) 2025-12-24
IL322175A (en) 2025-09-01
US20220313695A1 (en) 2022-10-06
US20250213565A1 (en) 2025-07-03
ES3055679T3 (en) 2026-02-13
UY37834A (es) 2019-02-28

Similar Documents

Publication Publication Date Title
DK3661514T3 (da) Mavacamten til behandling af hypertrofisk kardiomyopati
DK3501542T3 (da) Esketamin til behandling af depression
LT3810602T (lt) Junginiai
DK3512850T3 (da) Inhibitorer af menin-mll-interaktionen
DK3468966T3 (da) Inhibitorer af menin-mll-interaktionen
DK3785733T3 (da) Farmaceutisk sammensætning til behandling af autisme
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
EP3609871A4 (en) ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS
DK3503890T3 (da) Anvendelse af pridopidin til behandling af dystonier
DK3524255T3 (da) Sammensætning til behandling af acne
PT4039675T (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
DK4101454T3 (da) Sammensætninger til behandling af hypertension
DK3436074T3 (da) Thiazolidforbindelser til behandling af virale infektioner
DK3331610T3 (da) Midler til anvendelse til behandling af gliom
IL282311A (en) Use of reboxetine to treat narcolepsy
DK3318115T3 (da) Maskine til behandling af svinegylle
HUE065134T2 (hu) Vegyületek
DK3638293T5 (da) Sammensætninger til behandling af cancer
EP3850168C0 (fr) Elément de construction
DK3448340T3 (da) Applikationshjælpemiddel til behandling af sår
DK3478713T3 (da) Sammensætninger til behandling af amyloidose
DK3463328T3 (da) Seladelpar til behandling af primær biliær cholangitis
DK3618845T3 (da) Peptider til behandling af diabetes
EP3829866A4 (en) CONSTRUCTION ELEMENT
DK3672941T3 (da) Pyridylpyridonforbindelser